On Jan 07, 1984 Neuland Labs was incorporated in Hyderabad, India.
1986
On June 30, 1986 Neuland Made its first sale of Salbutamol Sulphate / Albuterol Sulfate.
1994
Neuland goes public and is oversubscribed by 70-folds. Proceeds from the Public issue were used to built a Large Scale production facility for the manufacture of Ranitidine HCI & Ciprofloxacin HCl.
1997
Neuland's First USFDA inspection for its flagship product albuterol sulfate (Unit-I).
1999
Neuland received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II).
2003
Neuland clocked more than 40% of its revenue from the regulated markets of US & EU.
2004
1.USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance. Also received cGMP clearance for both facilities from TGA, Austrlia.
2.Opening the North American office at New Jersey.
2006
Received Certifecate of suitability for product itraconazole, taking tally of Products with COS to 8
Second US Office started operations from California.
